Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
作者： Fabienne Baffert , Thomas Radimerski , Brian Gadbaw
DOI:
关键词:
摘要: The invention relates to a combination which comprises: (a) Compound A ((R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile) of Formula (A): [Chemical formula should be inserted here as it appears in Abstract paper form] or pharmaceutically acceptable salt thereof; and (b) B (N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide) (B): for simultaneous, concurrent, separate sequential use, especially use the treatment proliferative diseases. also pharmaceutical compositions comprising such method treating diseases, mammal, particularly human, with combination. present further commercial package product
lens.org参考文章(9)
Paola Guglielmelli, Alessandro M. Vannucchi, Costanza Bogani, mTOR/JAK INHIBITOR COMBINATION THERAPY ,(2012)
Sridurga Mithraprabhu, George Grigoriadis, Tiffany Khong, Andrew Spencer, Deactylase inhibition in myeloproliferative neoplasms Investigational New Drugs. ,vol. 28, pp. 50- 57 ,(2010) , 10.1007/S10637-010-9590-4
Yongchao Wang, Warren Fiskus, Daniel G. Chong, Kathleen M. Buckley, Kavita Natarajan, Rekha Rao, Atul Joshi, Ramesh Balusu, Sanjay Koul, Jianguang Chen, Andrew Savoie, Celalettin Ustun, Anand P. Jillella, Peter Atadja, Ross L. Levine, Kapil N. Bhalla, Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells Blood. ,vol. 114, pp. 5024- 5033 ,(2009) , 10.1182/BLOOD-2009-05-222133
Alfonso Quintás-Cardama, Kris Vaddi, Phillip Liu, Taghi Manshouri, Jun Li, Peggy A. Scherle, Eian Caulder, Xiaoming Wen, Yanlong Li, Paul Waeltz, Mark Rupar, Timothy Burn, Yvonne Lo, Jennifer Kelley, Maryanne Covington, Stacey Shepard, James D. Rodgers, Patrick Haley, Hagop Kantarjian, Jordan S. Fridman, Srdan Verstovsek, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. ,vol. 115, pp. 3109- 3117 ,(2010) , 10.1182/BLOOD-2009-04-214957
Gerlinde Wernig, Thomas Mercher, Rachel Okabe, Ross L. Levine, Benjamin H. Lee, D. Gary Gilliland, Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. ,vol. 107, pp. 4274- 4281 ,(2006) , 10.1182/BLOOD-2005-12-4824
Louis Storace, Jordan S. Fridman, Stacey Shepard, Krishna Vaddi, Argyrios G. Arvanitis, Nikoo Falahatpisheh, Maria Rafalski, Haisheng Wang, James D. Rodgers, Ravi Kumar Jalluri, Thomas P. Maduskuie, Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors ,(2006)
Jason Smith, Katherine J. Walsh, Cassandra L Jacobs, Qingquan Liu, Siyao Fan, Amee Patel, Sandeep Dave, Upregulated JAK/STAT Signaling Represents a Major Mode of Resistance to HDAC Inhibition In Lymphoma and Provides a Rationale for Novel Combination Therapy Blood. ,vol. 116, pp. 434- 434 ,(2010) , 10.1182/BLOOD.V116.21.434.434
Fabienne Baffert, Emeline Evrot, Nicolas Ebel, Claudia Roelli, Rita Andraos, Zhiyan Qian, Vincent Romanet, Masato Murakami, Thomas Radimerski, Improved Efficacy Upon Combined JAK1/2 and Pan-Deacetylase Inhibition Using Ruxolitinib (INC424) and Panobinostat (LBH589) in Preclinical Mouse Models of JAK2V617F-Driven Disease Blood. ,vol. 118, pp. 798- 798 ,(2011) , 10.1182/BLOOD.V118.21.798.798
Yongchao Wang, Warren Fiskus, Kavita Natarajan, Anand Jillella, Cornelia Quadt, Peter Ataja, Ross Levine, Kapil N. Bhalla, Co-Treatment with JAK2 Inhibitor TG101209 and Panobinostat or hsp90 Inhibitor AUY922 Attenuates Mutant JAK2-V617F Levels and Activity in Human Myeloproliferative Disorder Cells Blood. ,vol. 112, pp. 3739- 3739 ,(2008) , 10.1182/BLOOD.V112.11.3739.3739